Phenominer Database Results (25 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
BB.SHR-(Gnal-D18Mit9)/K serum total cholesterol level control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. blood cholesterol amount female 84 days 10 108.11 mg/dl 1.34 4.25 automated blood analysis opthalmic venous plexus 0.0 0 70104 324
BB.SHR-(Gnal-D18Mit9)/K serum triglyceride level control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. blood triglyceride amount male 84 days 15 159.29 mg/dl 9.83 38.05 automated blood analysis opthalmic venous plexus 0.0 0 70107 324
BB.SHR-(Gnal-D18Mit9)/K serum triglyceride level control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. blood triglyceride amount female 84 days 10 168.14 mg/dl 20.99 66.37 automated blood analysis opthalmic venous plexus 0.0 0 70108 324
BB.SHR-(Gnal-D18Mit9)/K blood CD45RC(high) CD4 T cell count to CD45RC(low) CD4 T cell count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 0.08 % 0.01 0.03 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84690 324
BB.SHR-(Gnal-D18Mit9)/K body weight control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. body mass male 84 days 15 324.0 g 6.45 25.0 body weighing method 0.0 0 70097 324
BB.SHR-(Gnal-D18Mit9)/K blood T lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 14 11.8 % 0.78 2.9 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75603 324
BB.SHR-(Gnal-D18Mit9)/K blood natural killer cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. natural killer cell quantity both 90 days 14 13.8 % 1.34 5.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84633 324
BB.SHR-(Gnal-D18Mit9)/K blood glucose level control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. blood glucose amount both 84 days 25 107.0 mg/dl 2.6 13.0 automated blood analysis opthalmic venous plexus 0.0 0 70111 324
BB.SHR-(Gnal-D18Mit9)/K percentage of study population developing diabetes mellitus during a period of time control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. glucose metabolism trait female 210 days 12 25.0 % manually read urine glucose test strip 0.0 0 70117 324
BB.SHR-(Gnal-D18Mit9)/K age at onset/diagnosis of diabetes mellitus control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. glucose metabolism trait female 210 days 12 103.0 d 4.91 17.0 manually read urine glucose test strip 0.0 0 70123 324
BB.SHR-(Gnal-D18Mit9)/K blood lymphocyte count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 14 2.0 x 1000 cells/ul 0.17 0.63 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75597 324
BB.SHR-(Gnal-D18Mit9)/K blood CD4 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 34.1 % 2.14 8.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84627 324
BB.SHR-(Gnal-D18Mit9)/K blood B lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. B cell quantity both 90 days 14 37.4 % 2.75 10.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75600 324
BB.SHR-(Gnal-D18Mit9)/K body weight control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. body mass female 84 days 10 206.0 g 9.49 30.0 body weighing method 0.0 0 70098 324
BB.SHR-(Gnal-D18Mit9)/K serum total cholesterol level control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. blood cholesterol amount male 84 days 15 111.97 mg/dl 3.69 14.29 automated blood analysis opthalmic venous plexus 0.0 0 70103 324
BB.SHR-(Gnal-D18Mit9)/K blood CD8 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD8-positive T cell quantity both 90 days 14 0.6 % 0.08 0.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84630 324
BB.SHR-(Gnal-D18Mit9)/K blood CD45RC(high) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 4.8 % 0.43 1.6 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84684 324
BB.SHR-(Gnal-D18Mit9)/K blood CD45RC(low) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 65.9 % 1.76 6.6 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84687 324
BB.SHR-(Gnal-D18Mit9)/K white blood cell count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. leukocyte quantity both 90 days 14 2.83 x 1000 cells/ul 0.23 0.87 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75606 324
BB.SHR-(Gnal-D18Mit9)/K systolic blood pressure control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. arterial blood pressure trait both 84 days-98 days 25 serial mean 122.0 mmHg 2.8 14.0 tail cuff volume pressure recording tail 0.0 0 average of 3 measurements, on 3 different days 70109 324
BB.SHR-(Gnal-D18Mit9)/K serum insulin level control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. blood insulin amount both 84 days 25 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay opthalmic venous plexus 0.0 0 ng/ml is unit 70100 324
BB.SHR-(Gnal-D18Mit9)/K percentage of study population developing diabetes mellitus during a period of time control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. glucose metabolism trait male 210 days 17 41.0 % manually read urine glucose test strip 0.0 0 70116 324
BB.SHR-(Gnal-D18Mit9)/K age at onset/diagnosis of diabetes mellitus control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. glucose metabolism trait male 210 days 17 101.0 d 5.09 21.0 manually read urine glucose test strip 0.0 0 70122 324
BB.SHR-(Gnal-D18Mit9)/K blood CD25 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 14 70.5 % 1.36 5.1 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84639 324
BB.SHR-(Gnal-D18Mit9)/K blood RT6.1 positive cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 14 3.4 % 0.67 2.5 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84636 324